The Dragon and the Tiger: Realties in the Control of Tuberculosis

Table 2

Size and characteristics of private TB market, adapted from Wells 2011.

Country	Incident cases (2008)	Coverage by first line private sector drugs*	% change in volume 2004–9	% of private market that is loose drugs	Number of manufacturers with 0.3% of private first line market share	Fluoroquinolone coverage of incident MDR-TB cases^#	Fluoroquinolone coverage of all incident cases^&
India	1,982,628	117%	−3	23%	6	41%	6.1%
China	1,301,322	23%	59	98%	9

*% of all incident cases that can be treated by first line drugs in private market (average across 4 first line drugs, assuming daily 6–8 month regimen). Data for this and other columns, unless noted, are for Q4 2008–Q3 2009.
^#Assuming daily dosing for 18 month regimen, and no use for drug-sensitive TB.
^&Assuming daily dosing for 6 month regimen, and no diagnosis of drug-resistant TB.